{"id":12815,"date":"2020-05-21T16:28:14","date_gmt":"2020-05-21T14:28:14","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=12815"},"modified":"2024-12-17T13:44:15","modified_gmt":"2024-12-17T12:44:15","slug":"biologia-de-cellules-mare-hematopoetiques-i-leucemogenesi","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-medicina-regenerativa\/programa-de-medicina-regenerativa\/biologia-de-cellules-mare-hematopoetiques-i-leucemogenesi\/","title":{"rendered":"Biologia de c\u00e8l\u00b7lules mare hematopo\u00e8tiques i leucemog\u00e8nesi"},"content":{"rendered":"\n

\n\t\tBiologia de c\u00e8l\u00b7lules mare hematopo\u00e8tiques i leucemog\u00e8nesi\n\t<\/h1>\n

\n\t\tResum\n\t<\/h3>\n\t

Les c\u00e8l\u00b7lules mare hematopo\u00e8tiques (HSC) es consideren la base de l’hematopoesi en adults. Actualment, la majoria d’aquests trastorns hematol\u00f2gics s\u00f3n curables mitjan\u00e7ant el trasplantament de HSC. No obstant aix\u00f2, la disponibilitat limitada de donants compatibles \u00f2ptims segueix sent un repte, especialment per a individus d’origen no cauc\u00e0sic o d’\u00e8tnia mixta. Les c\u00e8l\u00b7lules mare pluripotents humanes (PSC), incloses les c\u00e8l\u00b7lules mare embrion\u00e0ries (hESC) i les PSC indu\u00efdes (hiPSC), poden diferenciar-se in vitro<\/em> en diversos tipus de c\u00e8l\u00b7lules hematopo\u00e8tiques i podrien representar una font ideal de HSC personalitzades per a l’aplicaci\u00f3 cl\u00ednica. A m\u00e9s, les HSC derivades de pacients iPSC no nom\u00e9s representen un model invaluable de malaltia hematol\u00f2gica, sin\u00f3 que tamb\u00e9 poden proporcionar una plataforma basada en c\u00e8l\u00b7lules per al cribratge terap\u00e8utic. La producci\u00f3 de HSC d’empelt a partir de PSC humanes dependr\u00e0 de la recapitulaci\u00f3 precisa de la hematopoesi embrion\u00e0ria.<\/p>\n

23<\/h2>\n

Publicacions<\/h2>\n\t\t\t\t\"Hematopoietic-Stem-Cell-Biology-And-Leukemogenesis\"\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Identificar vies de desenvolupament involucrades en la generaci\u00f3 de c\u00e8l\u00b7lules mare hematopo\u00e8tiques per dirigir la diferenciaci\u00f3 de c\u00e8l\u00b7lules mare pluripotencials en c\u00e8l\u00b7lules hematopo\u00e8tiques cl\u00ednicament rellevants<\/p>\n

Desenvolupar models de desenvolupament de c\u00e8l\u00b7lules mare del c\u00e0ncer de sang basats en c\u00e8l\u00b7lules pluripotents indu\u00efdes.<\/p>\n

Aquests objectius es realitzaran combinant gen\u00f2mica, transcript\u00f2mica, edici\u00f3 de gens i t\u00e8cniques biol\u00f2giques cel\u00b7lulars.<\/p>\n\t\t\t\t\tPublicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

– Bigas A, Palma LG, Kartha GM, Giorgetti A. Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development<\/strong>. Stem Cells Transl. Med.<\/p>\n

– Kotmayer L, Romero Moya D, Marin Bejar O, Kozyra E, Catal\u00e0 A, Bigas A, Wlodarski MW, B\u00f6d\u00f6r C, Giorgetti A. GATA2 deficiency and MDS\/AML: Experimental strategies for disease modelling and future therapeutic prospects.<\/strong> Br J Haematol. 2022;199(4):482-495. doi:10.1111\/bjh.18330.<\/p>\n

– Pera J, Casta\u00f1o J, Casamitjana J, Giorgetti A, Romero Moya D. Generation of heterozygous SAMD9 CRISPR\/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation<\/strong>. Stem Cell Res. 2022;64102906-102906. doi:10.1016\/j.scr.2022.102906.<\/p>\n

– Casta\u00f1o J, Romero Moya D, Richaud Patin Y, Giorgetti A. Generation of two heterozygous GATA2 CRISPR\/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency<\/strong>. Stem Cell Res. 2021;55102445-102445. doi:10.1016\/j.scr.2021.102445. IF:2,02.<\/p>\n

– Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang JY, Storti B, Castano J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Basseres DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer<\/strong>. Commun Biol. 2021;4(1):370-370. doi:10.1038\/s42003-021-01897-6. IF:6,27.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t